Compare Cadila Healthcare with Jubilant Pharmova - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs JUBILANT PHARMOVA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE JUBILANT PHARMOVA CADILA HEALTHCARE/
JUBILANT PHARMOVA
 
P/E (TTM) x 36.7 15.0 244.7% View Chart
P/BV x 6.4 2.8 229.8% View Chart
Dividend Yield % 0.5 0.5 100.8%  

Financials

 CADILA HEALTHCARE   JUBILANT PHARMOVA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
JUBILANT PHARMOVA
Mar-19
CADILA HEALTHCARE/
JUBILANT PHARMOVA
5-Yr Chart
Click to enlarge
High Rs352898 39.2%   
Low Rs207618 33.4%   
Sales per share (Unadj.) Rs139.2572.0 24.3%  
Earnings per share (Unadj.) Rs11.836.2 32.5%  
Cash flow per share (Unadj.) Rs18.659.5 31.2%  
Dividends per share (Unadj.) Rs3.504.50 77.8%  
Dividend yield (eoy) %1.30.6 210.9%  
Book value per share (Unadj.) Rs101.4301.9 33.6%  
Shares outstanding (eoy) m1,023.74159.28 642.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.01.3 151.5%   
Avg P/E ratio x23.720.9 113.5%  
P/CF ratio (eoy) x15.012.7 118.2%  
Price / Book Value ratio x2.82.5 109.8%  
Dividend payout %29.812.4 239.5%   
Avg Mkt Cap Rs m286,033120,694 237.0%   
No. of employees `00013.42.4 560.9%   
Total wages/salary Rs m24,14519,260 125.4%   
Avg. sales/employee Rs Th10,632.738,120.6 27.9%   
Avg. wages/employee Rs Th1,801.28,058.4 22.4%   
Avg. net profit/employee Rs Th898.52,414.3 37.2%   
INCOME DATA
Net Sales Rs m142,53191,108 156.4%  
Other income Rs m1,139357 318.7%   
Total revenues Rs m143,67091,466 157.1%   
Gross profit Rs m24,19817,390 139.1%  
Depreciation Rs m6,9653,709 187.8%   
Interest Rs m3,4182,198 155.5%   
Profit before tax Rs m14,95411,840 126.3%   
Minority Interest Rs m2880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m3,1983,268 97.9%   
Profit after tax Rs m12,0445,770 208.7%  
Gross profit margin %17.019.1 88.9%  
Effective tax rate %21.427.6 77.5%   
Net profit margin %8.56.3 133.4%  
BALANCE SHEET DATA
Current assets Rs m87,15445,848 190.1%   
Current liabilities Rs m82,69420,897 395.7%   
Net working cap to sales %3.127.4 11.4%  
Current ratio x1.12.2 48.0%  
Inventory Days Days7157 125.8%  
Debtors Days Days9451 184.2%  
Net fixed assets Rs m133,23665,498 203.4%   
Share capital Rs m1,024159 642.8%   
"Free" reserves Rs m102,73347,930 214.3%   
Net worth Rs m103,75748,089 215.8%   
Long term debt Rs m32,14642,429 75.8%   
Total assets Rs m236,866114,685 206.5%  
Interest coverage x5.46.4 84.2%   
Debt to equity ratio x0.30.9 35.1%  
Sales to assets ratio x0.60.8 75.7%   
Return on assets %6.56.9 94.0%  
Return on equity %11.612.0 96.7%  
Return on capital %13.712.4 110.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52,75212,422 424.7%   
Fx outflow Rs m14,50417,227 84.2%   
Net fx Rs m38,248-4,805 -796.0%   
CASH FLOW
From Operations Rs m25,05411,215 223.4%  
From Investments Rs m-10,123-10,118 100.0%  
From Financial Activity Rs m-10,9426,574 -166.4%  
Net Cashflow Rs m3,9897,612 52.4%  

Share Holding

Indian Promoters % 74.8 45.6 164.0%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 8.3 8.7 95.4%  
FIIs % 5.9 21.2 27.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 21.1 52.1%  
Shareholders   44,069 23,815 185.0%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   DR. DATSONS LABS  BIOCON   FULFORD INDIA  ASTRAZENECA PHARMA  DIVIS LABORATORIES  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Asian Paints Rallies 7% Post Q4 Results(09:30 am)

Asian stock markets climbed today after US benchmarks halted a three-day slide, with signs of a strengthening labor market outweighing investors' concerns about rising inflation.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

The Worst Sector in the Market(Fast Profits Daily)

May 11, 2021

The worst sector in the stock market according to the charts.

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


May 14, 2021 10:00 AM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS